Publication: A comprehensive review of hla and severe cutaneous adverse drug reactions: Implication for clinical pharmacogenomics and precision medicine
Issued Date
2021-11-01
Resource Type
ISSN
14248247
Other identifier(s)
2-s2.0-85117949364
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pharmaceuticals. Vol.14, No.11 (2021)
Suggested Citation
Chiraphat Kloypan, Napatrupron Koomdee, Patompong Satapornpong, Therdpong Tempark, Mohitosh Biswas, Chonlaphat Sukasem A comprehensive review of hla and severe cutaneous adverse drug reactions: Implication for clinical pharmacogenomics and precision medicine. Pharmaceuticals. Vol.14, No.11 (2021). doi:10.3390/ph14111077 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/75981
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
A comprehensive review of hla and severe cutaneous adverse drug reactions: Implication for clinical pharmacogenomics and precision medicine
Abstract
Human leukocyte antigen (HLA) encoded by the HLA gene is an important modulator for immune responses and drug hypersensitivity reactions as well. Genetic polymorphisms of HLA vary widely at population level and are responsible for developing severe cutaneous adverse drug reactions (SCARs) such as Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), maculopapular exanthema (MPE). The associations of different HLA alleles with the risk of drug induced SJS/TEN, DRESS and MPE are strongly supportive for clinical considerations. Prescribing guidelines generated by different national and international working groups for translation of HLA pharmacogenetics into clinical practice are underway and functional in many countries, including Thailand. Cutting edge genomic technologies may accelerate wider adoption of HLA screening in routine clinical settings. There are great opportunities and several challenges as well for effective implementation of HLA genotyping globally in routine clinical practice for the prevention of drug induced SCARs substantially, enforcing precision medicine initiatives.